| Literature DB >> 34328682 |
Hanna M Hulshof1, Barbora Benova2, Pavel Krsek2, Martin Kyncl3, Maarten H Lequin4, Anezka Belohlavkova2, Petr Jezdik5, Kees P J Braun1, Floor E Jansen1.
Abstract
OBJECTIVE: Patients with tuberous sclerosis complex (TSC) present with drug-resistant epilepsy in about 60% of cases, and evaluation for epilepsy surgery may be warranted. Correct delineation of the epileptogenic zone (EZ) among multiple dysplastic lesions on MRI represents a challenging step in pre-surgical evaluation.Entities:
Keywords: epilepsy surgery; focal cortical dysplasia; magnetic resonance imaging; pre-surgical evaluation; tuberous sclerosis complex
Mesh:
Year: 2021 PMID: 34328682 PMCID: PMC8633464 DOI: 10.1002/epi4.12529
Source DB: PubMed Journal: Epilepsia Open ISSN: 2470-9239
FIGURE 1MRI abnormalities in TSC, shown on T2 weighted images. Tuber in the left occipital lobe, seen as a hyperintense lesion (blue arrow, A). Increased cortical thickness in the right parieto‐occipital region (blue arrows, B). Also, a SEGA is shown in the lateral ventricle, unrelated to patient's epilepsy (red arrows, B). Blurring of the gray‐white matter junction with a calcification in the right frontal lobe (blue arrows, C). Transmantle sign in the right parietal lobe, seen as a subcortical hyperintense lesion with a tail extending toward the ventricle (blue arrows, D). Also, a tuber is shown in the left occipital lobe, seen as a small subcortical hyperintense lesion (red arrow, D)
Summary of MRI findings in the whole cohort
| MRI findings | All patients | All ROIs |
|---|---|---|
| Tubers | 28 (100%) | 187 (30.3%) |
| Cysts | 6 (21.4%) | 11 (1.8%) |
| Calcifications | 11 (39.3%) | 13 (2.1%) |
| Increased cortical thickness | 21 (75.0%) | 34 (5.7%) |
| GWM junction blurring | 26 (92.9%) | 110 (17.9%) |
| Transmantle sign | 24 (85.7%) | 65 (10.6%) |
Abbreviation: GWM, gray‐white matter.
Summary of results of correlation between respective features and the EZ
| Metrics features | MHL's evaluation of EZ | MK's evaluation of EZ | MK vs MHL | |||
|---|---|---|---|---|---|---|
| KT |
| KT |
| KT |
| |
| No of abnormalities | 0.27 | <.001 | 0.31 | .010 | 0.69 | <.001 |
|
No. of abnormalities (incl. largest affected area) | 0.27 | <.001 | 0.302 | .011 | 0.697 | <.001 |
| GWM blurring | 0.25 | <.001 | 0.25 | <.001 | 0.33 | <.001 |
| Transmantle sign | 0.27 | <.001 | 0.23 | <.001 | 0.36 | <.001 |
| Increased thickness | 0.35 | <.001 | 0.29 | <.001 | 0.60 | <.001 |
| Cysts | −0.03 | .544 | −0.02 | .672 | −0.01 | .891 |
| Calcification | 0.26 | <.001 | 0.65 | <.001 | 1.00 | <.001 |
| Largest FCD‐affected area | 0.40 | <.001 | 0.39 | <.001 | 0.90 | <.001 |
| Tuber | 0.23 | <.001 | 0.14 | .013 | 0.60 | <.001 |
| No. of abnormalities in ROI (excl. calcifications) | 0.27 | <.001 | 0.30 | .011 | 0.70 | <.001 |
Abbreviations: EZ, epileptogenic zone; GWM, gray‐white matter; KT, Kendal's tau; MHL, Maarten H. Lequin; MK, Martin Kyncl.
Summary of the accuracy, positive predictive value, and false discovery rate for each feature
| Metrics features | MHL's evaluation of EZ | MK's evaluation of EZ | ||||
|---|---|---|---|---|---|---|
| Accuracy | PPV | FDR | Accuracy | PPV | FDR | |
| GWM blurring | 84% | 25% | 75% | 87% | 29% | 71% |
| Transmantle sign | 89% | 35% | 65% | 88% | 30% | 70% |
| Increased thickness | 92% | 53% | 47% | 89% | 34% | 66% |
| Cysts | 90% | 0% | 100% | 91% | 0% | 100% |
| Calcification | 92% | 75% | 25% | 97% | 67% | 33% |
| Largest FCD‐affected area | 92% | 60% | 40% | 92% | 56% | 44% |
| Tuber | 62% | 16% | 84% | 52% | 12% | 88% |
Abbreviations: EZ, epileptogenic zone; FDR, false discovery rate; GWM, gray‐white matter; MHL, Maarten H. Lequin; MK, Martin Kyncl; PPV, positive predictive value.
FIGURE 2Positive predictive value (PPV), false discovery rate (FDR), and accuracy across subjects for neuroradiologist 1 (A, MHL) and 2 (B, MK)
FIGURE 3Combinations of various features that can correctly identify the epileptogenic zone for each of the neuroradiologists